Literature DB >> 20655278

Long-term outcome of Tako-tsubo cardiomyopathy.

Costin N Ionescu1, Cesar A Aguilar-Lopez, Antoine E Sakr, Andre E Ghantous, Thomas J Donohue.   

Abstract

BACKGROUND: Current data suggest an excellent outcome for patients with Tako-tsubo cardiomyopathy (TC). The objectives of this study were to evaluate the long-term outcome and the prognostic implication of thrombolysis in myocardial infarction myocardial perfusion grade (TMPG) in patients with TC.
METHODS: Retrospective analysis of all patients diagnosed with TC at our hospital between 2003 and 2008.
RESULTS: During the five-year period, we identified 27 patients with TC out of 1374 cases of emergent left heart catheterisation (2%). Mean follow-up was 27 ± 16 months. The majority were Caucasian (81%) female (96%), postmenopausal (96%), with a mean age of 68 ± 14 years. A precipitating stressor event was found in 74% of the patients, 30% being gastrointestinal triggers. Fourteen patients (52%) reached a combined end point of all cause death, cardiogenic shock, sudden cardiac death and rehospitalisation for cardiac reasons. TMPG was abnormal in 37% cases with no correlation with the outcome.
CONCLUSIONS: The long-term outcome of patients with TC is worse than previously reported. TMPG does not correlate with the outcome in TC.
Copyright © 2010 Australasian Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655278     DOI: 10.1016/j.hlc.2010.06.667

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  9 in total

Review 1.  Takotsubo cardiomyopathy: Pathophysiology, diagnosis and treatment.

Authors:  Kazuo Komamura; Miho Fukui; Toshihiro Iwasaku; Shinichi Hirotani; Tohru Masuyama
Journal:  World J Cardiol       Date:  2014-07-26

2.  Recurrence of Takotsubo cardiomyopathy with coronary slow flow phenomenon.

Authors:  Tomotake Tokunou; Kenji Sadamatsu
Journal:  J Cardiol Cases       Date:  2012-03-16

3.  Tirofiban in Takotsubo cardiomyopathy. Atypical broken heart syndrome with extremely fast recovery: a case report.

Authors:  I Akpinar; Y S Salihoglu; M R Sayin; T Elri; T Karabag; S M Dogan; M Aydin
Journal:  Herz       Date:  2012-08-30       Impact factor: 1.443

4.  Broken heart syndrome, neurogenic stunned myocardium and stroke.

Authors:  Amit S Dande; Amrita S Pandit
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

5.  Response to Ponamgi et al. Comments on Khalighi et al. Takotsubo Cardiomyopathy: A Long Term Follow-up Shows Benefit with Risk Factor Reduction. J. Cardiovasc. Dev. Dis., 2015, 2, 273-281.

Authors:  Mohammad Umar Farooq; Koroush Khalighi
Journal:  J Cardiovasc Dev Dis       Date:  2016-01-26

6.  Kidney Failure among Patients with Takotsubo Syndrome or Myocardial Infarction: A Retrospective Analysis.

Authors:  Verena Bill; Ibrahim El-Battrawy; Marvin Kummer; Andreas Mügge; Assem Aweimer; Michael Behnes; Ibrahim Akin
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-09

7.  Clinical characteristics of takotsubo cardiomyopathy in north america.

Authors:  Saeed Ahmed; Patompong Ungprasert; Supawat Ratanapo; Tanveer Hussain; Erik P Riesenfeld
Journal:  N Am J Med Sci       Date:  2013-02

Review 8.  Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses?: A Systematic Analytical Review.

Authors:  Marie Batisse-Lignier; Bruno Pereira; Pascal Motreff; Romain Pierrard; Christelle Burnot; Charles Vorilhon; Salwan Maqdasy; Béatrice Roche; Francoise Desbiez; Guillaume Clerfond; Bernard Citron; Jean-René Lusson; Igor Tauveron; Romain Eschalier
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

9.  Takotsubo Cardiomyopathy: A Long Term Follow-up Shows Benefit with Risk Factor Reduction.

Authors:  Koroush Khalighi; Mohammad Umar Farooq; Thein Tun Aung; Swe Oo
Journal:  J Cardiovasc Dev Dis       Date:  2015-11-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.